NovaBay Pharmaceuticals

FDA Clears NovaBay's Novel Dual-Action Eye Infection Treatment NVC-422 for Clinical Trials

- NovaBay Pharmaceuticals receives FDA clearance for Investigational New Drug application of NVC-422, triggering a $1 million milestone payment from licensing partner Alcon. - NVC-422, the lead Aganocide compound, shows promise as the first treatment targeting both viral and bacterial conjunctivitis, addressing a significant gap in current therapeutic options. - The development targets the $1+ billion global ophthalmic anti-infective market, offering potential solution to increasing antibiotic resistance in bacterial conjunctivitis treatment.